NEW YORK, March 26 - Paradigm Genetics of Research Triangle Park, NC, today tossed its hat into the microarray processing business, aligning itself with the Agilent Technologies platform with the announcement of a co-marketing agreement with the No. 2 manufacturer of microarrays.
Under the agreement, Paradigm will be a preferred service provider for Agilent's microarray products. The agreement is in addition to a multi-year supply deal already in place with Agilent to service Paradigm's five-year $23.8 million toxicogenomics contract with the National Institute of Environmental Health Sciences, a deal that calls for the processing of thousands of DNA microarrays.
Paradigm, which trades on the Nasdaq exchange, restructured in April, laying off 20 percent of its workforce and replaced founder and CEO John Ryals with former Syngenta executive Heinrich Gugger.